Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 Return-on-Tangible-Equity is 19.62% as of Jun. 2026, which is 42% below its 10-year median of 33.96. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 896 Drug Manufacturers companies, Essex Bio-Technology ranks better than 83.15% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Essex Bio-Technology's annualized net income for the quarter that ended in Jun. 2026 was HK$221 Mil. Essex Bio-Technology's average shareholder tangible equity for the quarter that ended in Jun. 2026 was HK$1,129 Mil. Therefore, Essex Bio-Technology's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 19.62%.
The historical rank and industry rank for Essex Bio-Technology's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01061'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 24.31 Med: 33.96 Max: 41.08
Current: 24.31
During the past 13 years, Essex Bio-Technology's highest Return-on-Tangible-Equity was 41.08%. The lowest was 24.31%. And the median was 33.96%.
HKSE:01061's Return-on-Tangible-Equity is ranked better than 83.15% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.575
vs HKSE:01061: 24.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Essex Bio-Technology Return-on-Tangible-Equity Related Terms
Essex Bio-Technology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01061 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.62% mean?
Essex Bio-Technology (HKSE:01061) has a Return-on-Tangible-Equity of 19.62% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Essex Bio-Technology and its competitors. This is 42% below median its historical median of 33.96. Over the past decade, Essex Bio-Technology's Return-on-Tangible-Equity has ranged from 24.31 to 41.08. According to the industry distribution chart, Essex Bio-Technology ranks #151 out of 896 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is Essex Bio-Technology's Return-on-Tangible-Equity too high?
Essex Bio-Technology's current Return-on-Tangible-Equity of 19.62% is 42% below median its 10-year median of 33.96. Over the past 10 years, this metric has ranged from a low of 24.31 to a high of 41.08. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.58. Essex Bio-Technology's value of 19.62% is 159% above this industry median. Based on the distribution chart, Essex Bio-Technology ranks #151 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #151 out of 896 companies for Return-on-Tangible-Equity. This places Essex Bio-Technology in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.58. Essex Bio-Technology's value of 19.62% is 159% above this benchmark. Historically, Essex Bio-Technology's own Return-on-Tangible-Equity has ranged from 24.31 to 41.08 over the past decade. While the company's 10-year median is 33.96 vs. the industry median of 7.58, Essex Bio-Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.58, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current Return-on-Tangible-Equity of 19.62% is 159% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current Return-on-Tangible-Equity is 19.62%, which is 42% below median its own 10-year median of 33.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Return-on-Tangible-Equity is 19.62%, which is 42% below median its 10-year median of 33.96 and 159% above the Drug Manufacturers industry median of 7.58. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Return-on-Tangible-Equity is 19.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
Return-on-Tangible-Equity: 19.62% (42% below median its 10-year median of 33.96)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 159% above the Drug Manufacturers median (#151 of 896)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
